Lucy A Godley

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8097948/publications.pdf

Version: 2024-02-01

161 papers	14,597 citations	61687 45 h-index	22488 117 g-index
166 all docs	166 docs citations	166 times ranked	19156 citing authors

#	Article	IF	Citations
1	A practical guide to interpreting germline variants that drive hematopoietic malignancies, bone marrow failure, and chronic cytopenias. Genetics in Medicine, 2022, 24, 931-954.	1.1	9
2	Feasibility and limitations of cultured skin fibroblasts for germline genetic testing in hematologic disorders. Human Mutation, 2022, 43, 950-962.	1.1	15
3	Germline CHEK2 and ATM Variants in Myeloid and Other Hematopoietic Malignancies. Current Hematologic Malignancy Reports, 2022, 17, 94-104.	1.2	14
4	Breaking the spatial constraint between neighboring zinc fingers: a new germline mutation in GATA2 deficiency syndrome. Leukemia, 2021, 35, 264-268.	3.3	15
5	Inherited predisposition to haematopoietic malignancies: overcoming barriers and exploring opportunities. British Journal of Haematology, 2021, 194, 663-676.	1.2	20
6	Assessment of technical heterogeneity among diagnostic tests to detect germline risk variants for hematopoietic malignancies. Genetics in Medicine, 2021, 23, 211-214.	1.1	17
7	Inherited Susceptibility to Hematopoietic Malignancies in the Era of Precision Oncology. JCO Precision Oncology, 2021, 5, 107-122.	1.5	24
8	Germline variants drive myelodysplastic syndrome in young adults. Leukemia, 2021, 35, 2439-2444.	3.3	43
9	Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer. Leukemia, 2021, 35, 3245-3256.	3.3	32
10	RBL2 bi-allelic truncating variants cause severe motor and cognitive impairment without evidence for abnormalities in DNA methylation or telomeric function. Journal of Human Genetics, 2021, 66, 1101-1112.	1.1	2
11	Efficacy and tolerability of a modified pediatricâ€inspired intensive regimen for acute lymphoblastic leukemia in older adults. EJHaem, 2021, 2, 413-420.	0.4	4
12	Germline predisposition to hematopoietic malignancies. Human Molecular Genetics, 2021, 30, R225-R235.	1.4	19
13	Clinical features and survival outcomes in patients with chronic myelomonocytic leukemia arising in the context of germline predisposition syndromes. American Journal of Hematology, 2021, 96, E327-E330.	2.0	6
14	Study of inherited thrombocytopenia resulting from mutations in ETV6 or RUNX1 using a human pluripotent stem cell model. Stem Cell Reports, 2021, 16, 1458-1467.	2.3	14
15	Genetics of Myelodysplastic Syndromes. Cancers, 2021, 13, 3380.	1.7	9
16	The RUNX1 database (RUNX1db): establishment of an expert curated RUNX1 registry and genomics database as a public resource for familial platelet disorder with myeloid malignancy. Haematologica, 2021, 106, 3004-3007.	1.7	29
17	BET inhibitors enhance embryonic and fetal globin expression in erythroleukemia cell lines. Haematologica, 2021, 106, 3223-3227.	1.7	0
18	Anticipation in hematopoietic malignancies: biology, bias, or both?. Leukemia and Lymphoma, 2021, 62, 3070-3072.	0.6	0

#	Article	IF	Citations
19	Therapy-Related Myeloid Neoplasms in 109 Patients Following Radiation Monotherapy. Blood Advances, 2021, 5, 4140-4148.	2.5	6
20	Germline mutations in MDS/AML predisposition disorders. Current Opinion in Hematology, 2021, 28, 86-93.	1.2	15
21	The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma. Nature Communications, 2021, 12, 6468.	5.8	35
22	Deleterious Germline Variants Are Present in Patients with Myelodysplastic Syndrome of All Ages Treated with Related Allogeneic Stem Cell Transplantation. Blood, 2021, 138, 320-320.	0.6	0
23	Spacing Constraints of Neighboring Zinc Finger Modules within GATA2. Blood, 2021, 138, 3306-3306.	0.6	0
24	5-Hydroxymethylcytosine Profiles in Circulating Cell-Free DNA Associate with Disease Burden in Children with Neuroblastoma. Clinical Cancer Research, 2020, 26, 1309-1317.	3.2	22
25	Correct application of variant classification guidelines in germline RUNX1 mutated disorders to assist clinical diagnosis. Leukemia and Lymphoma, 2020, 61, 246-247.	0.6	2
26	Telomere biology disorder prevalence and phenotypes in adults with familial hematologic and/or pulmonary presentations. Blood Advances, 2020, 4, 4873-4886.	2.5	23
27	Identifying potential germline variants from sequencing hematopoietic malignancies. Blood, 2020, 136, 2498-2506.	0.6	27
28	Heterozygous germ line CSF3R variants as risk alleles for development of hematologic malignancies. Blood Advances, 2020, 4, 5269-5284.	2.5	23
29	Regulation of telomeric function by DNA methylation differs between humans and mice. Human Molecular Genetics, 2020, 29, 3197-3210.	1.4	4
30	RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML. Blood Advances, 2020, 4, 1131-1144.	2.5	102
31	Inherited Thrombocytopenia Caused by Germline ANKRD26 Mutation Should Be Considered in Young Patients With Suspected Myelodysplastic Syndrome. Journal of Investigative Medicine High Impact Case Reports, 2020, 8, 232470962093894.	0.3	6
32	HIF-1 directly induces TET3 expression to enhance 5-hmC density and induce erythroid gene expression in hypoxia. Blood Advances, 2020, 4, 3053-3062.	2.5	15
33	MYC Regulation of D2HGDH and L2HGDH Influences the Epigenome and Epitranscriptome. Cell Chemical Biology, 2020, 27, 538-550.e7.	2.5	14
34	How I curate: applying American Society of Hematology-Clinical Genome Resource Myeloid Malignancy Variant Curation Expert Panel rules for RUNX1 variant curation for germline predisposition to myeloid malignancies. Haematologica, 2020, 105, 870-887.	1.7	23
35	A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia. Blood Advances, 2020, 4, 599-606.	2.5	9
36	Expanding Use of a Modified Pediatric Intensive Regimen for Acute Lymphoblastic Leukemia (ALL) into an Older Adult Population: Feasibility and Efficacy Results. Blood, 2020, 136, 41-42.	0.6	2

#	Article	IF	Citations
37	Identifying potential germline variants from sequencing hematopoietic malignancies. Hematology American Society of Hematology Education Program, 2020, 2020, 219-227.	0.9	16
38	Using sequential next-generation sequencing assays to identify germline cancer predisposition variants.. Journal of Clinical Oncology, 2020, 38, 1581-1581.	0.8	1
39	Assessing the Feasibility and Limitations of Cultured Skin Fibroblasts for Germline Genetic Testing in Hematologic Disorders. Blood, 2020, 136, 35-36.	0.6	2
40	Therapy-Related Myeloid Neoplasms in 108 Patients Following Radiation Therapy Only. Blood, 2020, 136, 25-26.	0.6	0
41	Characterization of cancer comorbidity prior to allogeneic hematopoietic cell transplantation. Leukemia and Lymphoma, 2019, 60, 629-638.	0.6	4
42	5-Hydroxymethylcytosine Profiles Are Prognostic of Outcome in Neuroblastoma and Reveal Transcriptional Networks That Correlate With Tumor Phenotype. JCO Precision Oncology, 2019, 3, 1-12.	1.5	14
43	Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis. Cancer Discovery, 2019, , .	7.7	0
44	Somatic mutation panels: Time to clear their names. Cancer Genetics, 2019, 235-236, 84-92.	0.2	16
45	Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis. Cancer Discovery, 2019, 9, 778-795.	7.7	41
46	Inherited predisposition to myeloid malignancies. Blood Advances, 2019, 3, 2688-2688.	2.5	2
47	ClinGen Myeloid Malignancy Variant Curation Expert Panel recommendations for germline RUNX1 variants. Blood Advances, 2019, 3, 2962-2979.	2.5	110
48	When should transplant physicians think about familial blood cancers?. Advances in Cell and Gene Therapy, 2019, 2, e68.	0.6	4
49	Regulation of 5-Hydroxymethylcytosine Distribution by the TET Enzymes. RNA Technologies, 2019, , 229-263.	0.2	3
50	Feasibility and Outcomes of T-Cell Depleted Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML and High Risk MDS. Blood, 2019, 134, 3324-3324.	0.6	0
51	Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults. Biology of Blood and Marrow Transplantation, 2018, 24, 997-1004.	2.0	18
52	Germline Lysine-Specific Demethylase 1 (LSD1/KDM1A) Mutations Confer Susceptibility to Multiple Myeloma. Cancer Research, 2018, 78, 2747-2759.	0.4	56
53	MBD4: guardian of the epigenetic galaxy. Blood, 2018, 132, 1468-1469.	0.6	1
54	Hereditary Myelodysplastic Syndrome and Acute Myeloid Leukemia: Diagnosis, Questions, and Controversies. Current Hematologic Malignancy Reports, 2018, 13, 426-434.	1.2	17

#	Article	IF	Citations
55	Identifying patients with genetic predisposition to acute myeloid leukemia. Best Practice and Research in Clinical Haematology, 2018, 31, 373-378.	0.7	18
56	Prognostic tumor sequencing panels frequently identify germ line variants associated with hereditary hematopoietic malignancies. Blood Advances, 2018, 2, 146-150.	2.5	83
57	Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host. Nature, 2018, 557, 580-584.	13.7	296
58	A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia. Journal of Hematology and Oncology, 2018, 11, 4.	6.9	52
59	Myeloid Malignancy Variant Curation Expert Panel: An ASH-Sponsored Clingen Expert Panel to Optimize and Validate Acmg/AMP Variant Interpretation Guidelines for Genes Associated with Inherited Myeloid Neoplasms. Blood, 2018, 132, 5849-5849.	0.6	0
60	Development of a Data Portal for Aggregation and Analysis of Genomics Data in Familial Platelet Disorder with Predisposition to Myeloid Malignancy - the RUNX1.DB. Blood, 2018, 132, 5241-5241.	0.6	0
61	Final Results from a Phase I Trial Combining Selinexor with High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in Acute Myeloid Leukemia (AML). Blood, 2018, 132, 4073-4073.	0.6	0
62	Recognition of familial myeloid neoplasia in adults. Seminars in Hematology, 2017, 54, 60-68.	1.8	37
63	Germline ETV6 mutations and predisposition to hematological malignancies. International Journal of Hematology, 2017, 106, 189-195.	0.7	64
64	Genetic predisposition to hematologic malignancies: management and surveillance. Blood, 2017, 130, 424-432.	0.6	145
65	Therapy-related myeloid neoplasms: when genetics and environment collide. Nature Reviews Cancer, 2017, 17, 513-527.	12.8	270
66	Clinical Assessment and Diagnosis of Germline Predisposition to Hematopoietic Malignancies: The University of Chicago Experience. Frontiers in Pediatrics, 2017, 5, 252.	0.9	16
67	Altered hydroxymethylation is seen at regulatory regions in pancreatic cancer and regulates oncogenic pathways. Genome Research, 2017, 27, 1830-1842.	2.4	51
68	Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival. Haematologica, 2016, 101, 634-643.	1.7	30
69	Increased DNA methylation of Dnmt3b targets impairs leukemogenesis. Blood, 2016, 127, 1575-1586.	0.6	38
70	Novel germ line DDX41 mutations define families with a lower age of MDS/AML onset and lymphoid malignancies. Blood, 2016, 127, 1017-1023.	0.6	179
71	Identifying Inherited and Acquired Genetic Factors Involved in Poor Stem Cell Mobilization and Donor-Derived Malignancy. Biology of Blood and Marrow Transplantation, 2016, 22, 2100-2103.	2.0	42
72	Brca1 deficiency causes bone marrow failure and spontaneous hematologic malignancies in mice. Blood, 2016, 127, 310-313.	0.6	39

#	Article	IF	Citations
73	Genetic predisposition to leukemia and other hematologic malignancies. Seminars in Oncology, 2016, 43, 598-608.	0.8	58
74	Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapyâ€related leukemia. Cancer, 2016, 122, 304-311.	2.0	129
75	Evaluation of Patients and Families With Concern for Predispositions to Hematologic Malignancies Within the Hereditary Hematologic Malignancy Clinic (HHMC). Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 417-428.e2.	0.2	74
76	Incidence and predictors of respiratory viral infections by multiplex PCR in allogeneic hematopoietic cell transplant recipients 50 years and older including geriatric assessment. Leukemia and Lymphoma, 2016, 57, 1807-1813.	0.6	9
77	Correspondence Regarding the Consensus Statement fromÂtheÂWorldwide Network for Blood and Marrow Transplantation Standing Committee on Donor Issues. Biology of Blood and Marrow Transplantation, 2016, 22, 183-184.	2.0	24
78	Fumarate and Succinate Regulate Expression of Hypoxia-inducible Genes via TET Enzymes. Journal of Biological Chemistry, 2016, 291, 4256-4265.	1.6	234
79	Expanded Phenotypic and Genetic Heterogeneity in the Clinical Spectrum of FPD-AML: Lymphoid Malignancies and Skin Disorders Are Common Features in Carriers of Germline RUNX1 Mutations. Blood, 2016, 128, 1212-1212.	0.6	2
80	Integrative genomics reveals hypoxia inducible genes that are associated with a poor prognosis in neuroblastoma patients. Oncotarget, 2016, 7, 76816-76826.	0.8	33
81	TET-catalyzed 5-hydroxymethylcytosine regulates gene expression in differentiating colonocytes and colon cancer. Scientific Reports, 2015, 5, 17568.	1.6	50
82	Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia. Blood, 2015, 126, 2484-2490.	0.6	207
83	Epigenetic Control of Apolipoprotein E Expression Mediates Gender-Specific Hematopoietic Regulation. Stem Cells, 2015, 33, 3643-3654.	1.4	6
84	DNMT3B7 Expression Promotes Tumor Progression to a More Aggressive Phenotype in Breast Cancer Cells. PLoS ONE, 2015, 10, e0117310.	1.1	15
85	5-hydroxymethylcytosine in cancer: significance in diagnosis and therapy. Cancer Genetics, 2015, 208, 167-177.	0.2	77
86	TET2 Mutations Affect Non-CpG Island DNA Methylation at Enhancers and Transcription Factorâ€“Binding Sites in Chronic Myelomonocytic Leukemia. Cancer Research, 2015, 75, 2833-2843.	0.4	80
87	Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy. Nature Genetics, 2015, 47, 180-185.	9.4	299
88	Characterization of CpG sites that escape methylation on the inactive human X-chromosome. Epigenetics, 2015, 10, 810-818.	1.3	9
89	Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms. Cancer Cell, 2015, 27, 658-670.	7.7	341
90	DNA Methylation Dynamics of Germinal Center B Cells Are Mediated by AID. Cell Reports, 2015, 12, 2086-2098.	2.9	87

#	Article	IF	Citations
91	New themes in the biological functions of 5â€methylcytosine and 5â€hydroxymethylcytosine. Immunological Reviews, 2015, 263, 36-49.	2.8	48
92	Identifying Inherited and Acquired Genetic Factors Involved in Poor Stem Cell Mobilization and Donor-Derived Malignancy. Blood, 2015, 126, 3163-3163.	0.6	0
93	Linking the genetic architecture of cytosine modifications with human complex traits. Human Molecular Genetics, 2014, 23, 5893-5905.	1.4	36
94	A new family with a germlineANKRD26mutation and predisposition to myeloid malignancies. Leukemia and Lymphoma, 2014, 55, 2945-2946.	0.6	30
95	The Role of Gene Body Cytosine Modifications in MGMT Expression and Sensitivity to Temozolomide. Molecular Cancer Therapeutics, 2014, 13, 1334-1344.	1.9	40
96	DNA Hydroxymethylation Profiling Reveals that WT1 Mutations Result in Loss of TET2 Function in Acute Myeloid Leukemia. Cell Reports, 2014, 9, 1841-1855.	2.9	237
97	Hydroxymethylation at Gene Regulatory Regions Directs Stem/Early Progenitor Cell Commitment during Erythropoiesis. Cell Reports, 2014, 6, 231-244.	2.9	93
98	Large conserved domains of low DNA methylation maintained by Dnmt3a. Nature Genetics, 2014, 46, 17-23.	9.4	276
99	Inherited Predisposition to Acute Myeloid Leukemia. Seminars in Hematology, 2014, 51, 306-321.	1.8	85
100	Familial myelodysplastic syndrome/acute leukemia syndromes: a review and utility for translational investigations. Annals of the New York Academy of Sciences, 2014, 1310, 111-118.	1.8	95
101	On the Origin of Leukemic Species. Cell Stem Cell, 2014, 14, 421-422.	5.2	4
102	TET1-Mediated Hydroxymethylation Facilitates Hypoxic Gene Induction in Neuroblastoma. Cell Reports, 2014, 7, 1343-1352.	2.9	146
103	Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. Haematologica, 2014, 99, 1373-1379.	1.7	213
104	Genome-Wide Variation of Cytosine Modifications Between European and African Populations and the Implications for Complex Traits. Genetics, 2013, 194, 987-996.	1.2	117
105	Perturbations of 5-Hydroxymethylcytosine Patterning in Hematologic Malignancies. Seminars in Hematology, 2013, 50, 61-69.	1.8	14
106	Dnmt3b is a haploinsufficient tumor suppressor gene in Myc-induced lymphomagenesis. Blood, 2013, 121, 2059-2063.	0.6	44
107	Mechanism-Based Epigenetic Chemosensitization Therapy of Diffuse Large B-Cell Lymphoma. Cancer Discovery, 2013, 3, 1002-1019.	7.7	180
108	Recognizing familial myeloid leukemia in adults. Therapeutic Advances in Hematology, 2013, 4, 254-269.	1.1	55

#	Article	IF	Citations
109	2-Hydroxyglutarate inIDHmutant acute myeloid leukemia: predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levels. Leukemia and Lymphoma, 2013, 54, 408-410.	0.6	21
110	Proposal for the clinical detection and management of patients and their family members with familial myelodysplastic syndrome/acute leukemia predisposition syndromes. Leukemia and Lymphoma, 2013, 54, 28-35.	0.6	88
111	Genome-wide hydroxymethylation tested using the HELP-GT assay shows redistribution in cancer. Nucleic Acids Research, 2013, 41, e157-e157.	6.5	69
112	Alterations of 5-Hydroxymethylcytosine in Human Cancers. Cancers, 2013, 5, 786-814.	1.7	46
113	Allogeneic Hematopoietic Cell Transplantation Is Effective In Patients With Advanced Systemic Mastocytosis: A Multicenter Retrospective Analysis. Blood, 2013, 122, 2145-2145.	0.6	0
114	Large Conserved Domains Of Low DNA Methylation Maintained By 5-Hydroxymethycytosine and Dnmt3a. Blood, 2013, 122, 2406-2406.	0.6	0
115	Hematopoietic Stem Cell Function Is Regulated By Hormonal and Epigenetic Factors. Blood, 2013, 122, 1194-1194.	0.6	0
116	Effects ofTET2mutations on DNA methylation in chronic myelomonocytic leukemia. Epigenetics, 2012, 7, 201-207.	1.3	110
117	The Histone Code and Treatments for Acute Myeloid Leukemia. New England Journal of Medicine, 2012, 366, 960-961.	13.9	8
118	Profiles in Leukemia. New England Journal of Medicine, 2012, 366, 1152-1153.	13.9	21
119	Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nature Genetics, 2012, 44, 1179-1181.	9.4	692
120	Identifying familial myelodysplastic/acute leukemia predisposition syndromes through hematopoietic stem cell transplantation donors with thrombocytopenia. Blood, 2012, 120, 5247-5249.	0.6	19
121	Truncated DNMT3B Isoform DNMT3B7 Suppresses Growth, Induces Differentiation, and Alters DNA Methylation in Human Neuroblastoma. Cancer Research, 2012, 72, 4714-4723.	0.4	35
122	Pharmacogenomics of chemotherapeutic susceptibility and toxicity. Genome Medicine, 2012, 4, 90.	3.6	38
123	High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk Acute Myeloid Leukemia (AML). Leukemia and Lymphoma, 2012, 53, 445-450.	0.6	20
124	Dnmt3a is essential for hematopoietic stem cell differentiation. Nature Genetics, 2012, 44, 23-31.	9.4	916
125	Dynamic Regulation of 5-Hydroxymethylcytosine At the Î³-Globin Promoter During Erythroid Differentiation. Blood, 2012, 120, 824-824.	0.6	0
126	Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood, 2011, 118, 6438-6445.	0.6	158

#	Article	IF	Citations
127	5-hmCâ€“mediated epigenetic dynamics during postnatal neurodevelopment and aging. Nature Neuroscience, 2011, 14, 1607-1616.	7.1	746
128	Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine. Nature Biotechnology, 2011, 29, 68-72.	9.4	955
129	An Integrated Genomic Approach to the Assessment and Treatment of Acute Myeloid Leukemia. Seminars in Oncology, 2011, 38, 215-224.	0.8	21
130	Gene Mutations, Epigenetic Dysregulation, and Personalized Therapy in Myeloid Neoplasia: Are We There Yet?. Seminars in Oncology, 2011, 38, 196-214.	0.8	21
131	Tet2 Loss Leads to Increased Hematopoietic Stem Cell Self-Renewal and Myeloid Transformation. Cancer Cell, 2011, 20, 11-24.	7.7	1,105
132	TET2 Inactivation Results in Pleiotropic Hematopoietic Abnormalities in Mouse and IsÂa Recurrent Event during Human Lymphomagenesis. Cancer Cell, 2011, 20, 25-38.	7.7	792
133	Preference by Exclusion. Science, 2011, 331, 1017-1018.	6.0	3
134	Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors. Blood, 2011, 118, 2551-2555.	0.6	163
135	Dnmt3a Is Essential for Hematopoietic Stem Cell Differentiation. Blood, 2011, 118, 386-386.	0.6	7
136	Clofarabine-Melphalan-Alemtuzumab Conditioning for Allogeneic Hematopoietic Cell Transplantation: Final Report of a Phase I-II Study. Blood, 2011, 118, 1948-1948.	0.6	0
137	Limited Effect of TET2 Mutations on Promoter DNA Methylation in Chronic Myelomonocytic Leukemia. Blood, 2011, 118, 1365-1365.	0.6	1
138	Reduced Intensity Conditioning with Combined Haploidentical and Cord Blood Transplantation Results in Rapid Engraftment and Durable Remissions in Hematological Malignancies. Blood, 2011, 118, 830-830.	0.6	1
139	Myc-Mediated Lymphomagenesis Is Driven by DNA Methylation Changes Induced by DNMT3B7 Expression and Dnmt3b Heterozygosity. Blood, 2011, 118, 225-225.	0.6	0
140	A Phase II Prospective Feasibility Study of Clofarabine Cytoreduction Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients with Relapsed or Refractory Acute Leukemias and Advanced Myelodysplastic Syndromes. Blood, 2011, 118, 496-496.	0.6	0
141	Leukemic IDH1 and IDH2 Mutations Result inÂa Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation. Cancer Cell, 2010, 18, 553-567.	7.7	2,328
142	An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes. OncoTargets and Therapy, 2010, 3, 1.	1.0	25
143	DNMT3B7, a Truncated DNMT3B Isoform Expressed in Human Tumors, Disrupts Embryonic Development and Accelerates Lymphomagenesis. Cancer Research, 2010, 70, 5840-5850.	0.4	56
144	The Next Frontier for Stem Cell Transplantation. JAMA - Journal of the American Medical Association, 2010, 303, 1421.	3.8	14

#	Article	IF	Citations
145	Getting to the root of the stem cell in mutated chronic myeloid leukemia. Leukemia and Lymphoma, 2010, 51, 2147-2148.	0.6	1
146	Identification and molecular characterization of a novel 3â€² mutation inRUNX1in a family with familial platelet disorder. Leukemia and Lymphoma, 2010, 51, 1931-1935.	0.6	29
147	Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant. Leukemia and Lymphoma, 2010, 51, 995-1006.	0.6	16
148	Deletion of the der(9q) in chronic myeloid leukemia: the controversy continues. Leukemia and Lymphoma, 2009, 50, 871-872.	0.6	3
149	Therapy-Related Myeloid Leukemia. Seminars in Oncology, 2008, 35, 418-429.	0.8	272
150	The identification and characterisation of novelKITtranscripts in aggressive mast cell malignancies and normal CD34+ cells. Leukemia and Lymphoma, 2008, 49, 1567-1577.	0.6	10
151	Preliminary Results of Combined Haploidentical-Cord Blood Transplantation for Patients Lacking HLA Identical Donors. Blood, 2008, 112, 3015-3015.	0.6	1
152	Modulators of DNA methylation and histone acetylation. Update on Cancer Therapeutics, 2007, 2, 157-169.	0.9	5
153	HMGA2levels in CML: Reflective of miRNA gene regulation in a hematopoietic tumor?. Leukemia and Lymphoma, 2007, 48, 1898-1899.	0.6	5
154	The use of hypomethylating agents in the treatment of hematologic malignancies. Leukemia and Lymphoma, 2007, 48, 1676-1695.	0.6	37
155	Novel C-KIT Transcripts Identified in Mast Cell Leukemia: An Update of the Full Transcript and Itâ€™s Distribution.. Blood, 2007, 110, 2396-2396.	0.6	0
156	Phase I Study of XK469R (NSC 698215), a Quinoxaline Phenoxypropionic Acid Derivative, in Patients with Refractory Hematological Malignancies.. Blood, 2006, 108, 1952-1952.	0.6	0
157	New Cytogenetic Abnormalities Are Frequent in AML and MDS Relapsing after Allogeneic Hematopoietic Cell Transplantation (HCT).. Blood, 2006, 108, 3675-3675.	0.6	0
158	Leukemic Relapse after Allogeneic Stem Cell Transplantation with a T-Cell Depleted Reduced Intensity Conditioning (RIST) Regimen.. Blood, 2005, 106, 2022-2022.	0.6	1
159	Clinical Predictors of Transplant Related Mortality after Reduced Intensity Allogeneic Stem Cell Transplantation (RIST).. Blood, 2004, 104, 1145-1145.	0.6	11
160	Identical Novel C-Kit Transcripts in Two Patients with Mast Cell Leukemia.. Blood, 2004, 104, 2001-2001.	0.6	2
161	Fludarabine Melphalan and Alemtuzumab (Campath) Conditioning for Pts with High Risk Myeloid Malignancies. High Cure Rate for Pts with Low Leukemia Burden.. Blood, 2004, 104, 2321-2321.	0.6	1